Prosecution Insights
Last updated: November 20, 2026

Michael D Burkhart, USPTO Patent Examiner

Listed by the USPTO as BURKHART, MICHAEL D

Tech Center 1600 • Art Units: 1633 1638 1653

This examiner grants 62% of resolved cases

Analysis

This examiner is in Tech Center 1600 and Art Unit 1633, with 850 resolved cases. The allowance rate is 62.5%, and the median time to allowance is 1217 days. The 11.8% interview lift is positive but limited, suggesting that interviews are a useful supplement rather than the principal driver of outcomes.

The recorded companies are Hoffmann-La Roche Inc., Intellia Therapeutics Inc., and Ucl Business Ltd. The leading firms are LEYDIG VOIT & MAYER, LTD, Acuity Law Group, P.C., and ARRIGO, LEE, GUTTMAN & MOUTA-BELLUM LLP. Practitioners may emphasize precise written claim positioning and reserve interviews for targeted clarification.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

62.5%
Allow Rate
+2.5% vs TC avg
890
Total Applications
+11.8%
Interview Lift
1217
Avg Prosecution Days
Based on 850 resolved cases, 2023–2026

Rejection Statute Breakdown

5.1%
§101 Eligibility
19.2%
§102 Novelty
28.4%
§103 Obviousness
26.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17777741 COMPOSITIONS AND METHODS OF USING ENGINEERED FUSION PROTEINS THAT BIND G4C2 HUMAN REPEATS Non-Final OA The Regents of the University of California
17559934 METHOD FOR THE PRODUCTION OF AN ANTIBODY Final Rejection Hoffmann-La Roche Inc.
18670684 Chimeric Antigen Receptors with BCMA Specificity and Uses Thereof Non-Final OA Regeneron Pharmaceuticals, Inc.
18282061 GENE THERAPY COMPOSITION AND TREATMENT OF RIGHT VENTRICULAR ARRHYTHMOGENIC CARDIOMYOPATHY Final Rejection UCL BUSINESS LTD
18628222 METHODS FOR GENERATION OF PODOCYTES FROM PLURIPOTENT STEM CELLS AND CELLS PRODUCED BY THE SAME Non-Final OA PRESIDENT AND FELLOWS OF HARVARD COLLEGE
18915595 CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS Non-Final OA Purdue Research Foundation
19061415 Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses Thereof Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Michael D Burkhart's allowance rate?

62.5% of resolved applications examined by Michael D Burkhart were allowed (850 resolved cases), compared with 34.9% across Art Unit 1633 over the last five years.

Does an interview help with examiner Michael D Burkhart?

This examiner's interview lift is +11.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Michael D Burkhart take to allow a patent?

Applications allowed by Michael D Burkhart took 1,217 days on average from filing to allowance.

Which art unit does examiner Michael D Burkhart work in?

Michael D Burkhart examines applications in Art Unit 1633 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month